virginiamycin and Swine-Diseases

Griseoviridin, a known antibiotic produced by Streptomyces cacaoi subsp. cacaoi, was found to be active against Brachyspira hyodysenteriae--the bacterium causing swine dysentery. An in vitro synergism is observed when it is used in combination with viridogrisein--a simultaneously produced antibiotic. In mouse experiments, the effect of griseoviridin alone was less than that of lincomycin--a commercially available swine dysentery medication. However, a 1:1 mixture of griseoviridin and viridogrisein revealed a noticeable synergistic effect. In an evaluation using pigs artificially infected with B. hyodysenteriae, a large difference was not observed between the effect of griseoviridin alone and that in combination with viridogrisein. Nevertheless, griseoviridin alone exhibited a therapeutic effect superior to that of lincomycin.

Topics: Animals; Anti-Bacterial Agents; Drug Synergism; Dysentery; Lincomycin; Macrolides; Male; Mice; Mice, Inbred Strains; Microbial Sensitivity Tests; Molecular Structure; Peptides; Specific Pathogen-Free Organisms; Spirochaetales; Spirochaetales Infections; Swine; Swine Diseases; Virginiamycin

Clonal complex (CC) 9 is a prevalent livestock-associated (LA) MRSA clone in Asia whose pathogenicity in humans remains unknown.. In 2012, we identified a patient with CC9-MRSA infection linked to livestock. After screening 3328 clinical MRSA isolates from a national database, eight isolates (0.24%) collected between 1998 and 2012 were further confirmed to be of CC9. The detailed molecular features of the nine human CC9 strains and phylogenetic relatedness to animal CC9 strains were characterized with WGS. The antibiotic susceptibilities were determined and the clinical information was abstracted from medical records.. WGS grouped the CC9 strains into two clades, which were respectively associated with distinct toxome profiles, resistance gene profiles and staphylococcal cassette chromosomes (SCCmecXII for 7 isolates and SCCmecVT for 2 isolates). The SCCmecXII strains were phylogenetically related to animal CC9-MRSA strains, negative for Panton-Valentine leucocidin and 100% resistant to ciprofloxacin, erythromycin, clindamycin, gentamicin and tigecycline. Four of the seven SCCmecXII isolates were associated with invasive diseases including bacteraemia leading to death (2) and osteomyelitis (2). Two SCCmecXII isolates were from patients with exposure to pigs before development of the MRSA diseases.. The CC9-SCCmecXII MRSA prevailing in pigs in Asia is multidrug resistant and potentially pathogenic to humans. It is critical to continuously monitor the local epidemiology of MRSA and implement effective control measures to limit the spread of LA-MRSA between animals, to humans and in healthcare facilities.

Topics: Adult; Aged; Aged, 80 and over; Animals; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactams; Child, Preschool; Ciprofloxacin; Clindamycin; Drug Resistance, Multiple, Bacterial; Erythromycin; Farmers; Female; Gentamicins; Humans; Livestock; Male; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Middle Aged; Minocycline; Staphylococcal Infections; Swine; Swine Diseases; Taiwan; Tigecycline; Virginiamycin

Fifty-four quinupristin/dalfopristin-resistant Enterococcus faecium (QDREF) isolated from chickens and pigs during 2002-2003 in Korea were screened by PCR for the presence of streptogramin resistance genes vatD, vatE, and vgbA, and macrolide resistance gene ermB. None of the QDREF isolates carried vgbA and vatD genes, while vatE and ermB were detected in 9.2% and 74% of the isolates, respectively. Twenty-six percent (14/54) of the QDREF isolates contained none of the resistance determinants tested. Pulsed-field gel electrophoresis (PFGE) patterns revealed high heterogeneity: 47 different patterns for 54 QDREF evaluated. Identical PFGE types were observed in two pairs of chicken isolates and a pair of pig isolates, respectively, but chicken isolates did not share PFGE pattern with pig isolates, suggesting clonal spread of QDREF strain between the same species of animals but not between different species of animals. This is the first report, to our knowledge, of vatE-positive E. faecium isolates and also the first evidence of clonal spread of QDREF strain between animals in Korea.

Topics: Animals; Anti-Bacterial Agents; Chickens; Drug Resistance, Multiple, Bacterial; Enterococcus faecium; Gram-Positive Bacterial Infections; Korea; Poultry Diseases; Streptogramins; Swine; Swine Diseases; Virginiamycin

Topics: Animals; Anti-Bacterial Agents; Drug Resistance, Multiple, Bacterial; Enterococcus faecium; Gram-Positive Bacterial Infections; Humans; Poultry Diseases; Swine Diseases; Virginiamycin

Topics: Animal Welfare; Animals; Anti-Bacterial Agents; Chickens; European Union; Growth Substances; Legislation, Drug; Poultry Diseases; Swine; Swine Diseases; Virginiamycin

The aim of this study was to evaluate the effect of different antibiotics used as growth promoters on the control of porcine intestinal adenomatosis when administered in weaning, growing and fattening pig diets, according to Annex I of the European Union directive (70/524/EEC and its subsequent amendments to date) for the use of feed additives. On a farm with a previous history of proliferative enteropathy outbreaks, 648 weaned piglets (23 days old) were divided into nine experimental groups according to bodyweight and sex ratio, each group comprising four pens with 18 pigs in each pen. One group served the trial as a negative (unmedicated) control: another (the positive control) received monensin via feed at 100 p.p.m. up to the end of the growing phase (107 days old) and 50 p.p.m. up to slaughter age (156 days old). The remaining seven groups were offered feed with the addition of the following antibiotics: virginia-mycin (50-20 p.p.m.), avilamycin (40-20 p.p.m.), spiramycin (50-20 p.p.m.), zinc bacitracin (50-10 p.p.m.), avoparcin (40-20 p.p.m.), tylosin (40-20 p.p.m.) and salinomycin (60-30 p.p.m.), respectively. The performance of the pigs in the positive control group was very satisfying and among the highest in the trial, verifying earlier field studies. As a general conclusion it seems that all tested growth promoters had a beneficial effect compared with the untreated control, indicated by the decrease of mortality rate, the elimination of diarrhoeal incidence and the enhancement of growth performance, although the proliferative enteropathy control achieved by each substance was not always satisfactory. More specifically, the antibiotic growth promoters tested can be scaled according to their total efficacy as follows: 1. Salinomycin, tylosin, spiramycin; 2. Virginiamycin, zinc bacitracin, avilamycin; and 3. Avoparcin. Finally, it is considered that part of the growth promotion efficacy of the tested substances is due to their potential capacity to control porcine intestinal adenomatosis; thus, in future growth performance trials, the disease background of the trial farms must be examined, especially for porcine enteropathy challenges.

Topics: Abattoirs; Animals; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacitracin; Bacterial Infections; Disease Outbreaks; Female; Food, Fortified; Glycopeptides; Greece; Growth Substances; Ileitis; Ileum; Intestinal Mucosa; Male; Monensin; Oligosaccharides; Pyrans; Spiramycin; Swine; Swine Diseases; Tylosin; Virginiamycin

Topics: Animal Feed; Animals; Brachyspira hyodysenteriae; Drug Resistance, Microbial; Dysentery; Rectum; Specific Pathogen-Free Organisms; Spirochaetales Infections; Swine; Swine Diseases; Virginiamycin

Swine from a herd routinely fed subtherapeutic levels of chlortetracycline (CTC) were fed a diet containing 55 mg of CTC/kg, a diet containing 55 mg of virginiamycin/kg, or a control diet. All animals were inoculated with Salmonella typhimurium that was susceptible to tetracycline. The quantity, duration and prevalence of shedding of S. typhimurium were determined. The infecting organism was first recovered from the animals fed CTC or the control diet on d 2, from animals fed virginiamycin on d 7 and from animals in a second control group on d 10. The infecting organism was recovered in fewer samples obtained during the initial 7 d postinfection than in those obtained during the last 24 d of the study. Little transfer of resistance to the infecting organism seemed to have occurred from the resident microflora because only two isolates (1%) had resistant patterns that differed from that of the infecting organism. Feeding CTC or virginiamycin to swine did not significantly increase or prolong shedding of an experimentally infected tetracycline-susceptible strain of S. typhimurium. Neither antibiotic affected the drug resistance of the infecting organism.

Topics: Animals; Chlortetracycline; Diet; Drug Resistance, Microbial; Food Additives; Salmonella Infections, Animal; Salmonella typhimurium; Swine; Swine Diseases; Virginiamycin

Topics: Animals; Body Weight; Diet; Dysentery; Swine; Swine Diseases; Virginiamycin

Topics: Administration, Oral; Animal Feed; Animals; Drug Resistance, Microbial; Escherichia coli; Feces; Housing, Animal; Salmonella Infections, Animal; Salmonella typhimurium; Swine; Swine Diseases; Virginiamycin

Topics: Animals; Arsenates; Colon; Drug Resistance; Dysentery; Gentamicins; Hydroxyquinolines; Recurrence; Ronidazole; Swine; Swine Diseases; Virginiamycin

Topics: Animals; Anti-Bacterial Agents; Carbadox; Cyclic N-Oxides; Dysentery; Leucomycins; Quinoxalines; Swine; Swine Diseases; Treponema; Treponemal Infections; Virginiamycin

Virginiamycin, fed at a concentration of 110 mg/kg of feed for 2 weeks followed by concentrations of either 27.5 or 55 mg/kg for 3 weeks, was effective in treatment and control of experimentally induced swine dysentery. However, diarrhea recurred 4 days after withdrawal of medicated feed. Subsequently, the frequency of diarrhea decreased in 3 of 4 groups retreated with virginiamycin (110 mg/kg of feed) for 5 days. Feeding of virginiamycin (110 mg/kg) for 1 week after onset of diarrhea was of little value because of the development of a more severe (augmented) form of the disease after withdrawal of medicated feed. Feeding of virginiamycin (55 mg/kg) at the time of exposure and continuing for 3 weeks (followed by intermittent retreatments of 55 mg/kg) aided in treatment and control of swine dysentery. With this regimen, a few swine developed diarrhea during initial medication, but all developed diarrhea after withdrawal fo medicated feed. Frequency of diarrhea was less after each retreatment. This was attributed to the development of immunity from the recurring diarrhea.

Topics: Administration, Oral; Animal Feed; Animals; Dysentery; Swine; Swine Diseases; Virginiamycin

Serums from 119 swine exposed to swine dysentery inoculum, and medicated with various drugs, were tested for antibodies to the large spirochete, using the indirect fluorescent antibody test, and were compared in tests with known positive serums from 18 nonmedicated swine which had recovered naturally. An inverse relationship existed between the efficacy of the drug and the serum antibody titer (highest dilution of the serum producing immunofluorescence of large spirochetes). The more efficacious drugs or doses resulted in lesser development of serum antibody. Diarrhea usually seemed necessary for the development of serum antibody. With the less efficacious drugs, there were more days of diarrhea. Some swine had diarrhea but did not develop an antibody titer, and a few swine had a titer but did not develop diarrhea. Swine which developed a titer were more immune against reexposure with infective inoculum. The medicaments, especially those given at higher concentrations, seemed to resolve the diarrhea or prevent the development of diarrhea, occurrences which were necessary for the development of immunity.

Topics: Animals; Antibodies; Dysentery; Fluorescent Antibody Technique; Leucomycins; Lincomycin; Ronidazole; Spectinomycin; Spirochaetales; Spirochaetales Infections; Swine; Swine Diseases; Virginiamycin

Topics: Animals; Anti-Bacterial Agents; Dysentery; Swine; Swine Diseases; Virginiamycin